Thermo Fisher Scientific Stock Drops 3.65% with $10.02 Billion Trading Volume Ranking 47th in Market Activity

On June 17, 2025, Thermo Fisher Scientific (TMO) experienced a decline of 3.65% in its stock price, with a trading volume of 10.02 billion, ranking 47th in the day's market activity.

Thermo Fisher Scientific recently unveiled new mass spectrometers at the ASMS 2025 conference, featuring enhanced scan speeds, throughput, and multiplexing capabilities. These advancements are expected to significantly reduce biopharma research timelines and revolutionize applications in biopharma and omics research.

There has been speculation about Thermo Fisher Scientific's plan to sell parts of its diagnostics division for approximately $4 billion. This strategic move is seen as an effort to focus on innovation and higher-growth areas by shedding slower-growing assets. The potential divestiture has sparked discussions about its impact on the company's portfolio and stock performance, with some investors viewing it as a positive step towards future growth.

Members of Congress have been actively trading Thermo Fisher Scientific stock, with a total of 12 trades in the past six months. Notably, Representative Robert Bresnahan and Senator Markwayne Mullin have made multiple purchases and sales, indicating a mix of bullish and bearish sentiments among lawmakers.

Insider trading activity at Thermo Fisher Scientific has been predominantly bearish, with 25 sales and no purchases recorded in the past six months. Key executives, including the Chairman & CEO and the Sr. VP and CFO, have sold significant shares, which may reflect their outlook on the company's near-term prospects.

Institutional investors have shown varied interest in Thermo Fisher Scientific, with 1,144 adding shares to their portfolios and 1,353 decreasing their positions in the most recent quarter. Major moves include FMR LLC reducing its holdings by 26.7% and Capital World Investors increasing its stake by 17.3%, highlighting the mixed sentiment among large investors.

Thermo Fisher Scientific has received multiple government contracts totaling $121.19 million over the past year, with significant awards for maintenance and funding of mass spectrometers. These contracts underscore the company's role in providing critical scientific equipment to government agencies.

Analysts have issued mostly positive ratings for Thermo Fisher Scientific, with five firms recommending a buy or overweight position. Price targets for the stock range from $585 to $693, with a median target of $607.5, reflecting optimism about the company's future performance.